Business Context and Reporting Period
This Form 6-K filing by Banco Bradesco S.A. (Bradesco) covers the month of October 2009. The report details a strategic transaction approved on October 18, 2009, involving the integration of dental insurance activities between Odontoprev S.A. (OdontoPrev) and Bradesco Dental S.A. (Bradesco Dental).
Key Financial Metrics
The filing does not provide consolidated revenue, profit, cash flow, margins, debt, or liquidity metrics for Banco Bradesco S.A. for the period. The only financial data disclosed relates specifically to the combined dental insurance entity post-transaction:
- Combined Net Revenue: R$ 533 million (based on data as of June 30, 2009).
- Insured Lives: Approximately 4 million (based on data as of June 30, 2009).
Material Changes and Transaction Details
The primary material change is the execution of an Association Agreement to merge Bradesco Dental into OdontoPrev. Key structural outcomes include:
- Ownership Structure: Bradesco Saúde S.A. (direct controlling shareholder of Bradesco Dental) will hold 43.50% of OdontoPrev's capital stock. Existing OdontoPrev shareholders will hold 56.50%.
- Control: Bradesco Saúde and Mr. Randal Luiz Zanetti will jointly hold 51.06% of OdontoPrev's capital stock.
- Board Composition: The Board of Directors will consist of 8 members: 3 appointed by Bradesco Saúde (including the Chairman), 3 by Mr. Zanetti, and 2 independent members.
- Operational Synergy: OdontoPrev will enter an operating agreement with Bradesco to distribute dental plans through Bradesco's branch network nationwide.
Guidance, Risks, and Contingencies
The transaction is subject to several conditions precedent and risks:
- Regulatory Approval: Authorization from the Agência Nacional de Saúde Suplementar (National Agency for Supplementary Health) is required.
- Antitrust Review: The transaction must be presented to relevant antitrust agencies.
- Corporate Approvals: Final approval is needed from the Shareholders' Meetings of both OdontoPrev and Bradesco Dental, along with the execution of corporate documents and appraisal reports.
- Forward-Looking Statements: The filing includes standard disclaimers that future results may differ materially from expectations due to economic conditions, industry trends, and operating factors.
Investor Verification Checklist
- Confirm receipt of regulatory approval from the National Agency for Supplementary Health.
- Verify the outcome of antitrust agency reviews.
- Monitor the final approval status by the Shareholders' Meetings of OdontoPrev and Bradesco Dental.
- Assess the integration timeline for the commercial platforms and distribution network.
- Review the final appraisal reports to validate the transaction valuation.